title: Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
abstract: BACKGROUND
  Mepolizumab, a monoclonal anti-IL-5 antibody, is an effective corticosteroid-sparing agent for patients with Fip1-like 1/platelet-derived growth factor receptor α fusion (F/P)-negative hypereosinophilic syndrome (HES). Lymphocytic variant hypereosinophilic syndrome (L-HES) is characterized by marked overproduction of IL-5 by dysregulated T cells.
  
  
  OBJECTIVE
  To determine whether patients with L-HES respond to mepolizumab in terms of corticosteroid tapering and eosinophil depletion to the same extent as corticosteroid-responsive F/P-negative patients with HES and a normal T-cell profile.
  
  
  METHODS
  Patients enrolled in the mepolizumab trial were evaluated for L-HES on the basis of T-cell phenotyping and T-cell receptor gene rearrangement patterns, and their serum thymus-and-activation-regulated chemokine (TARC) levels were measured. Response to treatment was compared in patient subgroups based on results of these analyses.
  
  
  RESULTS
  Lymphocytic variant HES was diagnosed in 13 of 63 patients with HES with complete T-cell assessments. The ability to taper corticosteroids on mepolizumab was similar in patients with L-HES and those with a normal T-cell profile, although a lower proportion of patients with L-HES maintained eosinophil levels below 600/μL. Increased serum TARC levels (>1000 pg/mL) had no significant impact on the ability to reduce corticosteroid doses, but a lower proportion of patients with elevated TARC achieved eosinophil control on mepolizumab.
  
  
  CONCLUSIONS
  Mepolizumab is an effective corticosteroid-sparing agent for patients with L-HES. In some cases however, eosinophil levels remain above 600/μL, suggesting incomplete neutralization of overproduced IL-5 or involvement of other eosinophilopoietic factors.
authors.affiliation: Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. froufoss@ulb.ac.be
authors.forename: Florence
authors.initials: F
authors.lastname: Roufosse
authors.forename: Aurore
authors.initials: A
authors.lastname: de Lavareille
authors.forename: Liliane
authors.initials: L
authors.lastname: Schandené
authors.forename: Elie
authors.initials: E
authors.lastname: Cogan
authors.forename: Ann
authors.initials: A
authors.lastname: Georgelas
authors.forename: Lori
authors.initials: L
authors.lastname: Wagner
authors.forename: Liqiang
authors.initials: L
authors.lastname: Xi
authors.forename: Mark
authors.initials: M
authors.lastname: Raffeld
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Gleich
authors.forename: Amy
authors.initials: A
authors.lastname: Klion
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D054414:Chemokine CCL17 / Q000097:blood; D004311:Double-Blind Method; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology / Q000378:metabolism*; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C106230:CCL17 protein, human; D017252:CD3 Complex; D015704:CD4 Antigens; D054414:Chemokine CCL17; C508599:IL5 protein, human; D015848:Interleukin-5; C434107:mepolizumab; D011241:Prednisone
references.citation: Leuk Res. 2007 May;31(5):691-4
references.pmid: 17095087
references.citation: N Engl J Med. 1994 Feb 24;330(8):535-8
references.pmid: 8302319
references.citation: N Engl J Med. 1999 Oct 7;341(15):1112-20
references.pmid: 10511609
references.citation: Immunol Allergy Clin North Am. 2007 Aug;27(3):389-413
references.pmid: 17868856
references.citation: J Mol Diagn. 2002 Aug;4(3):137-43
references.pmid: 12169674
references.citation: J Am Acad Dermatol. 2003 Jan;48(1):23-30
references.pmid: 12522366
references.citation: Eur J Immunol. 2006 Jul;36(7):1882-91
references.pmid: 16810739
references.citation: Medicine (Baltimore). 1975 Jan;54(1):1-27
references.pmid: 1090795
references.citation: Ann Intern Med. 1982 Jul;97(1):78-92
references.pmid: 7046556
references.citation: Br J Dermatol. 1997 Jun;136(6):918-23
references.pmid: 9217826
references.citation: Annu Rev Med. 2009;60:293-306
references.pmid: 19630574
references.citation: J Allergy Clin Immunol. 2002 Sep;110(3):476-9
references.pmid: 12209097
references.citation: Clin Exp Rheumatol. 2007 Jan-Feb;25(1):17-22
references.pmid: 17417985
references.citation: Haematologica. 2009 Sep;94(9):1236-41
references.pmid: 19734416
references.citation: J Exp Med. 1996 Mar 1;183(3):1071-82
references.pmid: 8642249
references.citation: Br J Dermatol. 2003 Feb;148(2):203-10
references.pmid: 12588369
references.citation: N Engl J Med. 2008 Mar 20;358(12):1215-28
references.pmid: 18344568
references.citation: Allergy. 2002 Feb;57(2):173-7
references.pmid: 11929424
references.citation: J Clin Invest. 1996 Jan 15;97(2):309-15
references.pmid: 8567949
references.citation: J Allergy Clin Immunol. 2001 Mar;107(3):535-41
references.pmid: 11240957
references.citation: J Allergy Clin Immunol. 2008 Jun;121(6):1473-83, 1483.e1-4
references.pmid: 18410960
references.citation: J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3
references.pmid: 19910029